Premalatha Nandkumar
Internal Medicine · Elk Grove Vlg, ILNPI 1366471898
Payments from drug & device makers
Across 490 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$986
- AstraZeneca$617
- Pfizer$440
- Amarin Pharma, Inc.$434
- Bayer$393
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,43899%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 130 | $1,975 |
| Novo Nordisk | 87 | $986 |
| AstraZeneca | 42 | $617 |
| Pfizer | 24 | $440 |
| Amarin Pharma, Inc. | 22 | $434 |
| Bayer | 24 | $393 |
| Amgen | 24 | $382 |
| Johnson & Johnson | 23 | $362 |
| Lilly USA, LLC | 20 | $328 |
| Sanofi-aventis U.S. LLC | 13 | $237 |
| Merck | 15 | $227 |
| GSK | 8 | $143 |
| Astellas Pharma US Inc | 3 | $100 |
| Azurity Pharmaceuticals, Inc. | 5 | $99 |
| Kowa Pharmaceuticals America, Inc. | 6 | $87 |
| Boehringer Ingelheim | 6 | $84 |
| Novartis | 4 | $80 |
| Abbott | 5 | $76 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Corcept Therapeutics | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| IBSA Pharma Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$7,538 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $31,634 |
| FarxigaDapagliflozin Propanediol | 32 | $26,089 |
| EliquisApixaban | 18 | $24,753 |
| OzempicSemaglutide | 12 | $23,257 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $18,910 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $15,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,270 |
| LinzessLinaclotide | 11 | $7,589 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,027 |
| Levothyroxine Sodium | 295 | $3,561 |
| Novolog FlexpenInsulin Aspart | 11 | $3,304 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 79 | $2,732 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,487 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,029 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $2,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $143 | $35,15743 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $237 | $31,63432 claims |
| AstraZenecaFarxiga | $617 | $26,08932 claims |
| PfizerEliquis | $440 | $24,75318 claims |
| Novo NordiskOzempic | $986 | $23,25712 claims |
| MerckJanumet Xr | $227 | $18,91019 claims |
| AbbVieLinzess, Armour Thyroid, Synthroid | $1,975 | $9,87853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Elk Grove Vlg
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.